Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review.
J Clin Med
; 12(16)2023 Aug 12.
Article
in En
| MEDLINE
| ID: mdl-37629305
ABSTRACT
Objective:
to develop eligibility criteria for use in non-gynecological cancer patients.Methods:
We searched all the articles published in peer-reviewed journals up to March 2021. We utilized the PICOS standards and the following selection criteria menopausal women with a history of non-gynecological and non-breast cancer who underwent hormone replacement therapy (HRT) using various preparations (oestrogens alone or in combination with a progestogen, tibolone, or tissue selective oestrogen complex) and different routes of administration (including oral, transdermal, vaginal, or intra-nasal). We focused on randomized controlled trials as well as relevant extension studies or follow-up reports, specifically examining recurrence and mortality outcomes.Results:
Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women who are skin melanoma survivors using MHT have a longer survival rate than non-MHT survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rate than those who do not use MHT.Conclusions:
MHT is safe for women who have a history of colorectal, lung, or skin melanoma cancers.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Guideline
/
Risk_factors_studies
Language:
En
Journal:
J Clin Med
Year:
2023
Document type:
Article
Affiliation country:
Spain
Publication country:
CH
/
SUIZA
/
SUÍÇA
/
SWITZERLAND